Baseline characteristics of study cohorts with MPN-BP and post-MDS AML
Characteristic . | MPN-BP . | Post-MDS AML . | P . |
---|---|---|---|
No. of patients | 177 | 1104 | |
No. of centers | 73 | 165 | |
Patient-related | |||
Age at HCT, y | .78* | ||
Median (min-max) | 59 (40-82) | 59 (40-76) | |
Age at HCT, n (%), y | .31† | ||
40-49 | 30 (17) | 196 (18) | |
50-59 | 73 (41) | 429 (39) | |
60-69 | 59 (33) | 419 (38) | |
≥70 | 15 (8) | 60 (5) | |
Sex, n (%) | .30† | ||
Male | 116 (66) | 679 (62) | |
Female | 61 (34) | 425 (38) | |
Karnofsky score, n (%) | .53† | ||
90-100 | 88 (50) | 579 (52) | |
<90 | 84 (47) | 481 (44) | |
Missing | 5 (3) | 44 (4) | |
HCT-CI, n (%) | .14† | ||
0 | 33 (19) | 175 (16) | |
1-2 | 31 (18) | 195 (18) | |
≥3 | 50 (28) | 240 (22) | |
N/A, before 2007 | 61 (34) | 469 (42) | |
Missing | 2 (1) | 25 (2) | |
Disease-related | |||
Etiology of MPN at original diagnosis, n (%) | |||
PV | 46 (26) | 0 (0.0) | |
ET | 51 (29) | 0 (0.0) | |
PMF | 60 (34) | 0 (0.0) | |
MPN-U | 20 (11) | 0 (0.0) | |
N/A | 0 (0.0) | 1104 (100) | |
Time between diagnosis of MPN/MDS and AML, n (%), y | |||
Median (min-max) | 3 (0.0-30) | 0.3 (0.0-23) | |
<2 | 70 (40) | 764 (69) | |
2-5 | 28 (16) | 71 (6) | |
>5 | 63 (36) | 29 (3) | |
Missing | 16 (9) | 240 (22) | |
WBC at diagnosis, n (%), ×109/L | <.01† | ||
<30 | 121 (68) | 894 (81) | |
30-100 | 31 (18) | 95 (9) | |
>100 | 9 (5) | 21 (2) | |
Missing | 16 (9) | 94 (9) | |
Cytogenetics, n (%) | .76† | ||
Favorable | 1 (<1) | 14 (1) | |
Intermediate | 96 (54) | 642 (58) | |
Poor | 67 (38) | 371 (34) | |
Not tested | 5 (3) | 29 (3) | |
Missing | 8 (5) | 48 (4) | |
Disease status at HCT, n (%) | .21† | ||
In remission‡ | 101 (57) | 685 (62) | |
Active leukemia§ | 76 (43) | 419 (38) | |
Time from diagnosis to HCT, median (min-max) | 5 (0.3-321) | 5 (0.2-108) | .13* |
Time from diagnosis of AML to HCT, n (%), mo | .43† | ||
<6 | 105 (59) | 681 (62) | |
6-12 | 38 (21) | 253 (23) | |
>2 | 34 (19) | 170 (15) | |
Therapy-related, n (%) | |||
Induction therapy | .30† | ||
7+3 ± other | 100 (56) | 568 (51) | |
Cytarabine based | 18 (10) | 99 (9) | |
Hypomethylating | 7 (4) | 41 (4) | |
Other | 3 (2) | 62 (6) | |
No therapy given | 11 (6) | 69 (6) | |
Missing | 38 (21) | 265 (24) | |
Transplant-related | |||
Graft source, n (%) | .15† | ||
Bone marrow | 22 (12) | 185 (17) | |
Peripheral blood | 155 (88) | 919 (83) | |
Donor type, n (%) | .47† | ||
HLA-identical sibling | 54 (31) | 344 (31) | |
Other related | 13 (7) | 51 (5) | |
Well-matched URD | 83 (47) | 522 (47) | |
Partially matched/mismatched URD | 27 (15) | 187 (17) | |
D-R sex match, n (%) | .84† | ||
M-M | 76 (43) | 464 (42) | |
M-F | 36 (20) | 250 (23) | |
F-M | 39 (22) | 212 (19) | |
F-F | 25 (14) | 174 (16) | |
Missing | 1 (<1) | 4 (<1) | |
D-R CMV status, n (%) | .12† | ||
+/+ | 49 (28) | 344 (31) | |
+/− | 13 (7) | 104 (9) | |
−/+ | 58 (33) | 382 (35) | |
−/− | 53 (30) | 235 (21) | |
Missing | 4 (2) | 39 (4) | |
Conditioning regimen, n (%) | .54† | ||
TBI-MAC | 21 (12) | 157 (14) | |
Chemo-MAC | 72 (41) | 408 (37) | |
RIC/NST | 84 (47) | 539 (49) | |
GVHD prophylaxis, n (%) | .38† | ||
CNI + MMF ± others | 47 (27) | 313 (28) | |
CNI + MTX ± others | 99 (56) | 619 (56) | |
CNI ± others | 19 (11) | 118 (11) | |
Post-CY | 10 (6) | 30 (3) | |
Other | 1 (<1) | 16 (1) | |
Missing | 1 (<1) | 8 (<1) | |
In vivo T-cell depletion, n (%) | .05† | ||
No | 131 (74) | 735 (67) | |
Yes | 46 (26) | 369 (33) | |
Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .18† | ||
No | 129 (73) | 844 (76) | |
Yes | 46 (26) | 231 (21) | |
Missing | 2 (1) | 29 (3) | |
Year of transplant, n (%) | <.01† | ||
2001-2005 | 39 (22) | 347 (31) | |
2006-2010 | 72 (41) | 489 (44) | |
2011-2015 | 66 (37) | 268 (24) | |
Follow-up, median (min-max) | 71 (14-169) | 94 (3-193) |
Characteristic . | MPN-BP . | Post-MDS AML . | P . |
---|---|---|---|
No. of patients | 177 | 1104 | |
No. of centers | 73 | 165 | |
Patient-related | |||
Age at HCT, y | .78* | ||
Median (min-max) | 59 (40-82) | 59 (40-76) | |
Age at HCT, n (%), y | .31† | ||
40-49 | 30 (17) | 196 (18) | |
50-59 | 73 (41) | 429 (39) | |
60-69 | 59 (33) | 419 (38) | |
≥70 | 15 (8) | 60 (5) | |
Sex, n (%) | .30† | ||
Male | 116 (66) | 679 (62) | |
Female | 61 (34) | 425 (38) | |
Karnofsky score, n (%) | .53† | ||
90-100 | 88 (50) | 579 (52) | |
<90 | 84 (47) | 481 (44) | |
Missing | 5 (3) | 44 (4) | |
HCT-CI, n (%) | .14† | ||
0 | 33 (19) | 175 (16) | |
1-2 | 31 (18) | 195 (18) | |
≥3 | 50 (28) | 240 (22) | |
N/A, before 2007 | 61 (34) | 469 (42) | |
Missing | 2 (1) | 25 (2) | |
Disease-related | |||
Etiology of MPN at original diagnosis, n (%) | |||
PV | 46 (26) | 0 (0.0) | |
ET | 51 (29) | 0 (0.0) | |
PMF | 60 (34) | 0 (0.0) | |
MPN-U | 20 (11) | 0 (0.0) | |
N/A | 0 (0.0) | 1104 (100) | |
Time between diagnosis of MPN/MDS and AML, n (%), y | |||
Median (min-max) | 3 (0.0-30) | 0.3 (0.0-23) | |
<2 | 70 (40) | 764 (69) | |
2-5 | 28 (16) | 71 (6) | |
>5 | 63 (36) | 29 (3) | |
Missing | 16 (9) | 240 (22) | |
WBC at diagnosis, n (%), ×109/L | <.01† | ||
<30 | 121 (68) | 894 (81) | |
30-100 | 31 (18) | 95 (9) | |
>100 | 9 (5) | 21 (2) | |
Missing | 16 (9) | 94 (9) | |
Cytogenetics, n (%) | .76† | ||
Favorable | 1 (<1) | 14 (1) | |
Intermediate | 96 (54) | 642 (58) | |
Poor | 67 (38) | 371 (34) | |
Not tested | 5 (3) | 29 (3) | |
Missing | 8 (5) | 48 (4) | |
Disease status at HCT, n (%) | .21† | ||
In remission‡ | 101 (57) | 685 (62) | |
Active leukemia§ | 76 (43) | 419 (38) | |
Time from diagnosis to HCT, median (min-max) | 5 (0.3-321) | 5 (0.2-108) | .13* |
Time from diagnosis of AML to HCT, n (%), mo | .43† | ||
<6 | 105 (59) | 681 (62) | |
6-12 | 38 (21) | 253 (23) | |
>2 | 34 (19) | 170 (15) | |
Therapy-related, n (%) | |||
Induction therapy | .30† | ||
7+3 ± other | 100 (56) | 568 (51) | |
Cytarabine based | 18 (10) | 99 (9) | |
Hypomethylating | 7 (4) | 41 (4) | |
Other | 3 (2) | 62 (6) | |
No therapy given | 11 (6) | 69 (6) | |
Missing | 38 (21) | 265 (24) | |
Transplant-related | |||
Graft source, n (%) | .15† | ||
Bone marrow | 22 (12) | 185 (17) | |
Peripheral blood | 155 (88) | 919 (83) | |
Donor type, n (%) | .47† | ||
HLA-identical sibling | 54 (31) | 344 (31) | |
Other related | 13 (7) | 51 (5) | |
Well-matched URD | 83 (47) | 522 (47) | |
Partially matched/mismatched URD | 27 (15) | 187 (17) | |
D-R sex match, n (%) | .84† | ||
M-M | 76 (43) | 464 (42) | |
M-F | 36 (20) | 250 (23) | |
F-M | 39 (22) | 212 (19) | |
F-F | 25 (14) | 174 (16) | |
Missing | 1 (<1) | 4 (<1) | |
D-R CMV status, n (%) | .12† | ||
+/+ | 49 (28) | 344 (31) | |
+/− | 13 (7) | 104 (9) | |
−/+ | 58 (33) | 382 (35) | |
−/− | 53 (30) | 235 (21) | |
Missing | 4 (2) | 39 (4) | |
Conditioning regimen, n (%) | .54† | ||
TBI-MAC | 21 (12) | 157 (14) | |
Chemo-MAC | 72 (41) | 408 (37) | |
RIC/NST | 84 (47) | 539 (49) | |
GVHD prophylaxis, n (%) | .38† | ||
CNI + MMF ± others | 47 (27) | 313 (28) | |
CNI + MTX ± others | 99 (56) | 619 (56) | |
CNI ± others | 19 (11) | 118 (11) | |
Post-CY | 10 (6) | 30 (3) | |
Other | 1 (<1) | 16 (1) | |
Missing | 1 (<1) | 8 (<1) | |
In vivo T-cell depletion, n (%) | .05† | ||
No | 131 (74) | 735 (67) | |
Yes | 46 (26) | 369 (33) | |
Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .18† | ||
No | 129 (73) | 844 (76) | |
Yes | 46 (26) | 231 (21) | |
Missing | 2 (1) | 29 (3) | |
Year of transplant, n (%) | <.01† | ||
2001-2005 | 39 (22) | 347 (31) | |
2006-2010 | 72 (41) | 489 (44) | |
2011-2015 | 66 (37) | 268 (24) | |
Follow-up, median (min-max) | 71 (14-169) | 94 (3-193) |